The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: From hypoxic cell sensitisers to radiation-activated prodrugs

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 12, 2004, Pages 2459-2467

  Shibamoto, Yuta ^a   Sugie, Chikao ^a   Ito, Masato ^a   Ogino, Hiroyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Bioreductive agent; Doranidazole; Hypoxic cell sensitiser; KU 2285; Radiation activated prodrug; Tirapazamine

Indexed keywords

2 NITROIMIDAZOLE; 2 NITROIMIDAZOLE DERIVATIVE; 2,2 DIFLUORO N (2 HYDROXYETHYL) 3 (2 NITRO 1 IMIDAZOLYL)PROPIONAMIDE; 4 (2 NITRO 1 IMIDAZOLYLMETHOXY)CROTYL ALCOHOL; 5 NITROIMIDAZOLE DERIVATIVE; ALKYLATING AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTITRICHOMONAL AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIN; DORANIDAZOLE; ETANIDAZOLE; FLOXURIDINE; FLUOROURACIL; METRONIDAZOLE; MISONIDAZOLE; MITOMYCIN C; NIMORAZOLE; NITROIMIDAZOLE; PACLITAXEL; PRODRUG; PYRROLE DERIVATIVE; RADIOSENSITIZING AGENT; SANAZOLE; TIRAPAZAMINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL HYPOXIA; CLINICAL STUDY; CLINICAL TRIAL; DRUG ACTIVATION; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; ETHNOLOGY; HUMAN; HYPOXEMIA; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL RADIATION; INTRAOPERATIVE PERIOD; JAPAN; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; RADIATION DOSE; RADIOSURGERY; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ASIAN CONTINENTAL ANCESTRY GROUP; CELL HYPOXIA; CLINICAL TRIALS; EXPERT TESTIMONY; HUMANS; IMIDAZOLES; NEOPLASMS; NITROIMIDAZOLES; PRODRUGS; RADIATION; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 10644256629     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.12.2459     Document Type: Review

References (59)

1. ADAMS GE, HASAN NM, JOINER MC: Radiation, hypoxia and genetic stimulation: implications for future therapies. Radiother. Oncol. (1997) 44:101-109.
2. HOECKEL M, SCHLENGER K, ARAL B, MITZE M, SCHAEFFER U, VAUPEL P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. (1996) 56 4509-4515.
3. NORDSMARK M, OVERGAARD M, OVERGAARD J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. (1996) 41 31-39.
4. BRIZEL DM, SCULLY SP, HARRELSON JM et al.: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer-Res. (1996) 56:941-943.
5. HORSMAN MR: Measurement of tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42:701-704.
6. KAANDERS JHAM, WIJFFELS KIEM, MARRES HAM et al.: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. (2002) 62:7066-7074.
7. YANG DJ, WALLACE S, CHERIF A et al.: Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology (1995) 194:795-800.
8. 31P magnetic resonance spectroscopy in human soft tissue tumours. Acta Oncol. (1997) 36:565-571.
9. KOONG AC, MEHTA VK, LE QT et al.: Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. (2000) 48:919-922.
10. OKUNIEFF P, HOECKEL M, DUNPHY EP et al.: Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int. J. Radiat. Oncol. Biol. Phys. (1993) 26:631-636.
11. RAMPLING R, CRUICKSHANK G, LEWIS AD, FITZSIMMONS SA, WORKMAN P: Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. (1994) 29:427-431.
12. COLEMAN CN: Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J. Natl. Cancer Inst. (1988) 80:310-317.
13. WEINMANN M, WELZ S, BAMBERG M: Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology. Curr. Med. Chem. Anti-Canc. Agents (2003) 3:364-374.
14. URTASUN RC, BAND PR, CHAPMAN JD, FELDSTEIN ML: Radiation plus metronidazole for glioblastoma. N. Engl. J. Med. (1977) 296 757.
15. ADAMS GE, FLOCKHART IR, SMITHEN CE, STRATFORD IJ, WARDMAN P, WATTS ME: Electron-affinic sensitization VII. A correlation between structures, one-electron reduction potentials and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat. Res. (1976) 67:9-20.
16. OVERGAARD J, HANSEN HS, ANDERSEN AP et al.: Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int. J. Radiat. Oncol. Biol. Phys. (1989) 16 1065-1068.
17. OVERGAARD J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. (1994) 6 509-518.
18. LEE DJ, COSMATOS D, MARCIAL VA et al.: Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. (1995) 32:567-576.
19. ESCHWEGE F, SANCHO-GARNIER H, CHASSAGNE D et al.: Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. (1997) 39:275-281.
20. OVERGAARD J, OVERGAARD M, NIELSEN OS, PEDERSEN AK, TIMOTHY AR: A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br. J. Cancer (1982) 46:904-911.
21. OVERGAARD J, HANSEN HS, OVERGAARD M et al.: A randomized double-blind Phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of die Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother. Oncol. (1998) 46:135-146.
22. OVERGAARD J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. (1994) 6 509-518.
23. SHIBAMOTO Y, SAKANO K, KIMURA R et al.: Radiosensitization in vitro and in vivo by 3-nitrotriazoles. Int. J. Radiat. Oncol. Biol. Phys. (1986) 12:1063-1066.
24. SHIBAMOTO Y, SASAI K, SAKAGUCHI M et al.: Evaluation of a new 2-nitroimidazole nucleoside analogue, RK-28 as a radiosensitizer for clinical use. Int. J. Radiat. Biol. (1991) 59:105-115.
25. OYA N, SHIBAMOTO Y, SASAI K et al.: Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficacy and toxicity. Int. J. Radiat. Oncol. Biol. Phys. (1995) 33: 119-127.
26. SHIBAMOTO Y, KUBOTA T, KISHII K, TSUJITANI M: Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother. Oncol. (2000) 56:265-270.
27. SHIBAMOTO Y, NISHIMOTO S, SHIMOKAWA K et al.: Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys. (1989) 16 1045-1048.
28. SASAI K, NISHIMOTO S, SHIMOKAWA K et al.: A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. (1991) 20:1249-1254.
29. BERLIN JD, ROTHENBERG M: Chemotherapy for resectable and advanced pancreatic cancer. Oncology (2001) 15:1241-1249.
30. SHIBAMOTO Y, MANABE T, OHSHIO G et al.: High-dose intraoperative radiotherapy for unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. (1996) 34:57-63.
31. SHIBAMOTO Y, MANABE T, BABA N et al.: High dose, external beam and intraoperative radiotherapy in the treatment of resectable and unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. (1990) 19:605-611.
32. SASAI K, SHIBAMOTO Y, MANABE T et al.: Pharmacokinetics of intratumoral RK-28, a new hypoxic radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. (1992) 24:959-963.
33. HUILGOL NG, CHATTERJEE N, MEHTA AR: An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. (1996) 34:1121-1124.
34. NEMOTO K, SHIBAMOTO Y, OHMAGARI J et al.: Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy. Anticancer Drugs (2001) 12 1-6.
35. SUNAMURA M: Phase I clinical trial for the effect of a radiosensitizer, PR-350 (doranidazole) combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. Proceedings of the 2nd International Conference of the International Society of Intraoperative Radiation Therapy, Boston, USA, October 26-28 (2000):125.
36. SHIBAMOTO Y, TAKAHASHI M, ABE M: A Phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy. Radiother. Oncol. (1996) 40:55-58.
37. SHIBAMOTO Y, OHSHIO G, HOSOTANI R et al.: A Phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy. Br. J. Cancer (1997) 76 1474-1479.
38. SHIBATA T, SHIBAMOTO Y, SASAI K et al.: Assessment of micronucleus induction in SCCVII cells treated with bioreductive agents, WIN 59075(SR4233) and mitomycin C, under aerobic and hypoxic conditions. Mutat. Res. (1995) 342:171-177.
39. ZEMAN EM, BROWN JM, LEMMON MJ, HIRST VK, LEE WW: SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. (1986) 12 1239-1242.
40. BROWN JM, LEMMON MJ: Potentiation by the hypoxic cytotoxin SR-4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. (1990) 50:7745-7749.
41. SHIBATA T, SHIBAMOTO Y, SASAI K et al.: Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. Jpn. J. Cancer Res. (1996) 87:98-104.
42. VON PAWEL J, VON ROEMELING R, GATZEMEIER U et al.: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol. (2000) 18 1351-1359.
43. LARA PN JR, FRANKEL P, MACK PC et al.: Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a California Cancer Consortium Phase I and molecular correlative study. Clin. Cancer Res. (2003) 9:4356-4362.
44. AQUINO VM, WEITMAN SD, WINICK NJ et al.: Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a Pediatric Oncology Group study. J. Clin. Oncol. (2004) 22:1413-1419.
45. SHULMAN LN, BUSWELL L, RIESE N et al.: Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int. J. Radiat. Oncol. Biol. Phys. (1999) 44:349-353.
46. RISCHIN D, PETERS L, HICKS R et al.: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. (2001) 19 535-542.
47. DEL ROWE J, SCOTT C, WERNER-WASIK M et al.: Single-arm, open-label Phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. (2000) 18:1254-1259.
48. DIRIX LY, TONNESEN F, CASSIDY J et al.: EO9 Phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur. J. Cancer (1996) 32A:2019-2022.
49. HAFFTY BG, SON YH, WILSON LD et al.: Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig. (1997) 5:235-245.
50. MCCARTHY HO, YAKKUNDI A, MCERLANE V et al.: Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. (2003) 10:40-48.
51. PATTERSON LH, MCKEOWN SR, RUPARELIA K et al.: Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br. J. Cancer (2000) 82:1984-1990.
52. NISHIMOTO S, HATTA H, UESHIMA H, KAGIYA T: 1-(5′-fluoro-6′-hydroxy-5′,6′ -dihydrouracil-5′-yl)-5-fluorouracil, a novel N(1)-C(5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J. Med. Chem. (1992) 35 2711-2712.
53. SHIBAMOTO Y, ZHOU L, HATTA H, MORI M, NISHIMOTO S: A novel class of antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001) that releases 5-fluorouracil upon hypoxic irradiation. Jpn. J. Cancer Res. (2000) 91:433-438.
54. MORI M, HATTA H, NISHIMOTO S: Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2′-oxocycloalkyl)uracils as a new class of radiation-activated antitumor prodrugs. J. Org. Chem. (2001) 65 4641-4647.
55. SHIBAMOTO Y, ZHOU L, HATTA H, MORI M, NISHIMOTO S: In vivo evaluation of a novel antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Int. J. Radiat. Oncol. Biol. Phys. (2001) 49:407-413.
56. SHIBAMOTO Y, MIMASU Y, HATTA H, NISHIMOTO S: In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2′ -deoxyuridine activated by hypoxic irradiation. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58:397-402.
57. AHN CO, WARE DC, DENNY WA, WILSON WR: Optimization of the auxiliary ligand shell of cobalt (III) (8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs. Radiat. Res. (2004) 162:315-325.
58. VAN LAAR JAM, RUSTUM YM, ACKLAND SP, VAN GROENINGEN CJ, PETERS GJ: Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer (1998) 34:296-306.
59. SHIBAMOTO Y, MIMASU Y, TACHI Y, HATTA H, NISHIMOTO S: Comparison of 5-fluorouracil and 5-fluoro-2′-deoxyuridine as an effector in radiation-activated prodrug. J. Chemother. (2002) 14 390-396.